TRU NIAGEN® Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations
July 24 2019 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer
product, Tru Niagen® (nicotinamide riboside) is now available in
all seven Whole Foods Market locations across Ontario, in addition
to select Pure Pharmacy locations, Fullscript Canada, and online.
ChromaDex supplies Tru Niagen to stores via its relationship with
specialty distributor CLM Health Group.
ChromaDex CEO Rob Fried stated, “Whole Foods’ dedication to
bringing innovative, quality health and wellness products to its
consumers makes it a natural partner for ChromaDex as we continue
our retail expansion in Canada.”
Tru Niagen joins Whole Foods as the store’s newest product in
the energy category based on its strong clinical results and
scientific research.
Tru Niagen is a breakthrough supplement clinically proven to
increase your NAD (nicotinamide adenine dinucleotide) levels which
stimulate cellular energy production and support cellular repair.
Decreased NAD levels have been associated with many age-related
declines in overall health. NAD precursors such as nicotinamide
riboside (NR) have been the subject of rigorous preclinical safety
and toxicology studies laying the groundwork for the published
clinical studies that demonstrate safety and efficacy.
Tru Niagen is available on store shelves at all seven Whole
Foods Market locations in Ontario as of July 24, as well as on
amazon.ca and truniagen.ca.
For additional information on the science supporting Tru Niagen
visit www.truniagen.ca.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Senior Director of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024